Be mindful of these potential side effects
Currently, designing and producing personalized peptide vaccines is a time-consuming and costly process, but with new sequencing technologies, bioinformatics, and techniques for predicting T-cell epitopes, this may become a highly valuable tool in the future
(Milano: Spinger), 863979

coverage for seniors and income-based programs | | Quebec | Covered (RAMQ) | Type 2 diabetes, failed on other oral agents | Exception Drug | Covered under RAMQ public plan with medication d'exception status | | Manitoba | Covered (Pharmacare) | Type 2 diabetes | Exception Drug Status | Income-based deductible applies before coverage kicks in | | Saskatchewan | Covered (Drug Plan) | Type 2 diabetes, inadequate control | Exception Drug Status | Requires Exception Drug Status application | | Nova Scotia | Covered (Pharmacare) | Type 2 diabetes | Exception Status | Programs for seniors and income assistance recipients | | New Brunswick | Covered (Drug Plans) | Type 2 diabetes | Special Authorization | Available through NB Drug Plan | | Prince Edward Island | Covered (Drug Programs) | Type 2 diabetes | Special Authorization | Limited to eligible program participants | | Newfoundland and Labrador | Covered (NLPDP) | Type 2 diabetes | Special Authorization | Newfoundland and Labrador Prescription Drug Program | | Northwest Territories | Covered (NIHB/EHB) | Type 2 diabetes | Special Authorization | Extended Health and Social Services | | Nunavut | Covered (NIHB/EHB) | Type 2 diabetes | Approval required | Limited coverage programs | | Yukon | Covered (Drug Programs) | Type 2 diabetes | Approval required | Pharmacare and chronic disease programs | A pattern emerges: every province covers Ozempic for type 2 diabetes, but not one covers it purely for weight management through public drug plans as of early 2026

Without a specialized delivery system, glutathione has notoriously low bioavailability
Aliment Pharmacol Ther 13(4):443452